ENGLISH ABSTRACT
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

[Expression and prognostic value of proliferating cell nuclear antigen in hepatocellular carcinoma patients received preoperative transcatheter arterial chemoembolization].

BACKGROUND & OBJECTIVE: Proliferating cell nuclear antigen (PCNA) could indicate cell proliferation of hepatocellular carcinoma (HCC), while the impact of preoperative transcatheter arterial chemoembolization (TACE) on cell proliferation of HCC is still uncertain. This study was to investigate the expression and prognostic value of PCNA in HCC patients underwent preoperative TACE.

METHODS: The expression of PCNA in 91 specimens of HCC with preoperative TACE (TACE group) and 50 specimens of HCC without preoperative TACE (non-TACE group) was detected by immunohistochemistry. The expression of PCNA between the 2 groups after stratification were compared. Correlation of PCNA expression to tumor recurrence was analyzed.

RESULTS: PCNA was expressed in cell nuclei. The positive rates of PCNA were 67.0% in TACE group and 66.0% in non-TACE group (P>0.05). In patients with disseminated nodules, portal vein invasion and poorly differentiated tumor, the positive rates of PCNA were significantly lower in TACE group than in non-TACE group, respectively. In patients who underwent curative resection after preoperative TACE, the positive rates of PCNA were significantly higher in recurrence group than in non-recurrence group (77.8% vs. 47.1%, P<0.05). The 1-, 3-, and 5-year disease-free survival rates were significantly higher in PCNA-negative group than in PCNA-positive group (83.2% vs. 55.8%, 62.1% vs. 31.8%, and 53.2% vs. 23.6%, P<0.01).

CONCLUSIONS: Preoperative TACE inhibit cell proliferation of the HCC with disseminated nodules, portal vein invasion or poor differentiation. The expression of PCNA is closely correlated to postoperative recurrence of HCC patients who underwent preoperative TACE.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app